Turalio (pexidartinib) / Daiichi Sankyo  >>  Phase 2
Welcome,         Profile    Billing    Logout  

13 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Turalio (pexidartinib) / Daiichi Sankyo
NCT01217229: Safety and Efficacy Study of PLX3397 in Adults With Relapsed or Refractory Hodgkin Lymphoma

Completed
2
20
US
PLX3397
Daiichi Sankyo, Inc., Plexxikon
Hodgkin Lymphoma
04/12
04/12
NCT01499043: Pilot Study of PLX3397 in Patients With Advanced Castration-Resistant Prostate Cancer (CRPC)

Terminated
2
6
US
PLX3397
Daiichi Sankyo, Inc., Plexxikon
Prostate Cancer
03/13
03/13
NCT01349036: A Phase 2 Study of PLX3397 in Patients With Recurrent Glioblastoma

Terminated
2
38
US
PLX3397, Pexidartinib
Daiichi Sankyo, Inc., Plexxikon
Recurrent Glioblastoma
11/13
11/13
2016-000429-38: A Study to Evaluate Pexidartinib for Mild to Moderate Alzheimer’s Disease

Suspended
2
34
Europe
Pexidartinib Capsules, PLX3397 HCl, Capsule
Plexxikon Inc., Plexxikon Inc.
Alzheimer's Disease, Alzheimer's Disease, Diseases [C] - Nervous System Diseases [C10]
 
 
PIANO, NCT02071940 / 2013-002073-22: PLX3397 KIT in Acral aNd mucOsal Melanoma

Completed
2
7
Europe
PLX3397, Targeted therapy
The Christie NHS Foundation Trust, Cancer Research UK, Christie Charitable Funds
Malignant Melanoma
03/21
03/21
NCT04703322: A Study of Pexidartinib in Tenosynovial Giant Cell Tumor in Japan

Recruiting
2
21
Japan
Pexidartinib, TURALIO™, PLX3397
Daiichi Sankyo Co., Ltd.
Tenosynovial Giant Cell Tumor
02/25
11/26
I-SPY 2, NCT01042379: I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

Hourglass Jan 2023 - Dec 2023 : From P2 I-SPY 2 trial for invasive breast cancer
Checkmark Presentation of data from I-SPY trial for HR+/HER2- and TNBC breast cancer at SABCS 2022
Dec 2022 - Dec 2022: Presentation of data from I-SPY trial for HR+/HER2- and TNBC breast cancer at SABCS 2022
Checkmark Data from trial evaluating T-DM1+pertuzumab in the adjuvant setting
Nov 2018 - Nov 2018: Data from trial evaluating T-DM1+pertuzumab in the adjuvant setting
More
Recruiting
2
5000
US
Standard Therapy, Paclitaxel (Taxol); Doxorubicin (Adriamycin), AMG 386 with or without Trastuzumab, AMG 386 (Trebananib); (Trastuzumab) Herceptin, AMG 479 (Ganitumab) plus Metformin, Ganitumab, MK-2206 with or without Trastuzumab, (Trastuzumab) Herceptin, AMG 386 and Trastuzumab, AMG 386 (Trebananib); Trastuzumab (Herceptin), T-DM1 and Pertuzumab, T-DM1 (Trastuzumab emtansine); Pertuzumab (Perjeta), Pertuzumab and Trastuzumab, Pertuzumab (Perjeta); Trastuzumab (Herceptin), Ganetespib, ABT-888, Veliparib, Neratinib, PLX3397, Pembrolizumab - 4 cycle, Talazoparib plus Irinotecan, Patritumab and Trastuzumab, Pembrolizumab - 8 cycle, SGN-LIV1A, Durvalumab plus Olaparib, SD-101 + Pembrolizumab, Tucatinib plus trastuzumab and pertuzumab, Cemiplimab, Cemiplimab plus REGN3767, Trilaciclib with or without trastuzumab + pertuzumab, Trilaciclib (G1T28); Pertuzumab (Perjeta); Trastuzumab (Herceptin), SYD985 ([vic-]trastuzumab duocarmazine), Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) + Carboplatin with or without trastuzumab, Oral Paclitaxel + Encequidar (Oraxol); Dostarlimab (TSR-042); Trastuzumab (Herceptin), Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) with or without trastuzumab, Amcenestrant, SAR439859, Amcenestrant + Abemaciclib, Amcenestrant (SAR439859), Abemaciclib (Verzenio), Amcenestrant + Letrozole, Amcenestrant (SAR439859), Letrozole (Femara), ARX788, ARX788 + Cemiplimab, VV1 + Cemiplimab, VOYAGER V1™, VSV-IFNβ-NIS, Datopotamab deruxtecan, Dato-DXd, Datopotamab deruxtecan + Durvalumab, Zanidatamab, Lasofoxifene, Z-endoxifen, ARV-471, ARV-471 + Letrozole
QuantumLeap Healthcare Collaborative
Breast Neoplasms, Breast Cancer, Breast Tumors, Angiosarcoma, TNBC - Triple-Negative Breast Cancer, HER2-positive Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Tumor, Hormone Receptor Negative Tumor, Early-stage Breast Cancer, Locally Advanced Breast Cancer
12/30
12/31
NCT01790503: A Phase 1b/2 Study of PLX3397 + Radiation Therapy + Temozolomide in Patients With Newly Diagnosed Glioblastoma

Completed
1b/2
65
US
PLX3397, Pexidartinib, Radiation Therapy, Temozolomide, TMZ, Temodar
Daiichi Sankyo, Inc., Plexxikon
Patients With Newly Diagnosed Glioblastoma
11/17
03/20
NCT01349049: Phase 1/2 Safety and Efficacy of PLX3397 in Adults With Relapsed or Refractory Acute Myeloid Leukemia (AML)

Completed
1/2
90
US
PLX3397, Plexxikon 3397
Daiichi Sankyo, Inc., Plexxikon
Acute Myeloid Leukemia
01/15
01/18
NCT01596751: Phase Ib/II Study of PLX 3397 and Eribulin in Patients With Metastatic Breast Cancer

Completed
1/2
67
US
PLX3397, Eribulin, Halaven, E7389
Hope Rugo, MD, Susan G. Komen Breast Cancer Foundation, Plexxikon
Metastatic Breast Cancer
07/17
07/19
KEYNOTE-103, NCT02452424: A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors

Checkmark In combination with pexidartinib for melanoma & solid tumors
Jul 2019 - Dec 2019: In combination with pexidartinib for melanoma & solid tumors
Terminated
1/2
78
US
PLX3397, Pexidartinib, Pembrolizumab, Keytruda, MK-3475, SCH 900475
Daiichi Sankyo, Inc., Plexxikon, Merck Sharp & Dohme LLC
Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Gastrointestinal Stromal Tumor (GIST), Ovarian Cancer
08/18
10/18
2016-003291-47: POLERISE - Peidartinib and Enzalutamide in metastatic castration resistant prostate cancer.

Terminated
1/2
100
Europe
Pexidartinib, Xtandi, PLX3397, MDV3100, Capsule, Xtandi
University Hospital Southampton NHS Trust, Cancer Research UK, Plexxikon Pharmaceuticals
Metastatic Castration Resistant Prostate Cancer, Advanced, Diseases [C] - Cancer [C04]
 
 
NCT02584647: PLX3397 Plus Sirolimus in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath Tumors

Active, not recruiting
1/2
43
US
PLX3397, No other name, Sirolimus, Rapamune
Gulam Manji, Daiichi Sankyo
Sarcoma, Malignant Peripheral Nerve Sheath Tumors
07/23
06/24

Download Options